Li, S., Meng, L., Liu, H., Kan, S., Cong, L., Li, Z., Liu, Z., Xu, X., Han, W., Wang, J., Chu, Y., Yi, C., Liu, L. (2025). Efficacy and safety of second-line therapy with serplulimab, lenvatinib, and paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) for whom immunochemotherapy failed: A multicenter, single-arm, phase II trial (STILL).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e16075